MGC Pharmaceuticals delivers record consecutive weekly sales growth post launch of new Mercury Pharma line
MGC Pharmaceuticals Ltd (ASX:MXC) (OTCMKTS:MGCLF) (FRA:H5O) delivered consecutive record week-on-week sales and revenue growth through September and October – exceeding A$225,000 in the past four weeks alone.
The European based bio-pharma company specialising in the production and development of phytocannabinoid-derived medicines delivered on the key platforms of the business strategy and saw very strong growth in the number of sales, up more than 65% to over 7,000 units, since June 30, 2020.
While the domestic order pipeline is strong through until at least the end of 2020, there are also increasing orders from both Brazil and the UK, placing the company well on track to achieving record sales for the December quarter.
Lower overall cost base
MGC Pharma chief executive and managing director Roby Zomer said: “It is increasingly brought to our attention that one of the major inhibiting factors for patient access to medicinal cannabis in Australia, and globally, is the high price point that comes with high-quality medications that are not covered by insurance.
“We are constantly streamlining our operations in order to lower our overall cost base, to ensure we can meet our obligation to increase patient access to affordable, high-quality medicinal cannabis products.
“We are seeing the results of this strategy through the increase in patient demand and sales volumes.
Formal launch of Mercury Pharma product line
The sharp rise has been largely attributed to the recent formal launch of its industry-leading, affordable Mercury Pharma product line into the Australian and Brazilian markets, and the Australian Import Licence granted to the company in July.
This licence allows for the direct importation of any MGC Pharma Schedule 4 and Schedule 8 medicinal cannabis products into Australia.
The recent strong growth in prescribed units and sales has largely been in the Australian market where demand is exceeding the company’s expectations.
Expansion of the Mercury Pharma product line to include the entire range, combined with a more affordable price point for the products, has led a strong increase in demand through numerous channels including Australia’s leading medicinal cannabis distributor, Cannvalate.
In Australia, the products are being sold through pharmacies while in Brazil, they are directly provided to patients, which provides a further reduction in the final price to patients.
On target for key monthly milestone
Over the year, the company has executed a number of strategic initiatives such as new distribution agreements into key markets and the launch of a new range of affordable, high-quality products – Mercury Pharma.
The results of these initiatives are gaining significant traction in the market, including the recent world-first direct-to-patient delivery of high THC medicine in Brazil.
All these ensure the company is well-placed to deliver on its stated milestone objective of achieving 5,000 units per month/cashflow breakeven status in the first half of 2021.
TGA CBD scheduling changes
The company said its growing commercial presence in Australia put it in a unique position to take advantage of the upcoming changes announced by the Therapeutic Goods Administration (TGA) on September 9 – placing low-dose CBD on Schedule 3 – Pharmacist Only Medicine of the SUSMP (The Poisons Standard).
The company has launched a clinical program seeking advice from regulatory and clinical advisors, and the TGA to finalise a drug development plan and launch the required clinical research in early 2021.
MGC Pharma is one of only a handful of companies in Australia with the capacity to achieve a successful registration of a Schedule 3 product on the Australian Register of Therapeutic Goods.
An approval would secure the company as a market leader while providing access to significant revenues, it added.
No impact from COVID-19 in Slovenia
MGC Pharma said that the 30-day epidemic declared in Slovenia did not affect current operations as it had approval from the government to continue production due to the pharmaceutical nature of the business.
It has strict protocols in place to protect the health and well-being of its team, which operates in two independent shifts, thereby managing infection risk to enable the continuity of production.
Story by ProactiveInvestors
Source: https://www.proactiveinvestors.com/companies/news/931847/mgc-pharmaceuticals-delivers-record-consecutive-weekly-sales-growth-post-launch-of-new-mercury-pharma-line-931847.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world. Anyone can join. Anyone can contribute. Anyone can become informed about their world. "United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
LION'S MANE PRODUCT
Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules
Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, but it benefits growth of Essential Gut Flora, further enhancing your Vitality.
Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity. Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins. Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system. Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome. Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function. Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.
